Literature DB >> 27270772

Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status.

Marie Schoumacher1,2, Stéphanie Le Corre1,3, Alexandre Houy1,4, Eskeatnaf Mulugeta1,3, Marc-Henri Stern1,4, Sergio Roman-Roman1,2, Raphaël Margueron1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27270772     DOI： 10.1038/nm.4098

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  5 in total

1.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

2.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

3.  Patient-derived xenografts recapitulate molecular features of human uveal melanomas.

Authors:  Cécile Laurent; David Gentien; Sophie Piperno-Neumann; Fariba Némati; André Nicolas; Bruno Tesson; Laurence Desjardins; Pascale Mariani; Audrey Rapinat; Xavier Sastre-Garau; Jérôme Couturier; Philippe Hupé; Leanne de Koning; Thierry Dubois; Sergio Roman-Roman; Marc-Henri Stern; Emmanuel Barillot; J William Harbour; Simon Saule; Didier Decaudin
Journal:  Mol Oncol       Date:  2013-02-26       Impact factor: 6.603

Review 4.  The Polycomb complex PRC2 and its mark in life.

Authors:  Raphaël Margueron; Danny Reinberg
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

5.  Loss of BAP1 function leads to EZH2-dependent transformation.

Authors:  Lindsay M LaFave; Wendy Béguelin; Richard Koche; Matt Teater; Barbara Spitzer; Alan Chramiec; Efthymia Papalexi; Matthew D Keller; Todd Hricik; Katerina Konstantinoff; Jean-Baptiste Micol; Benjamin Durham; Sarah K Knutson; John E Campbell; Gil Blum; Xinxu Shi; Emma H Doud; Andrei V Krivtsov; Young Rock Chung; Inna Khodos; Elisa de Stanchina; Ouathek Ouerfelli; Prasad S Adusumilli; Paul M Thomas; Neil L Kelleher; Minkui Luo; Heike Keilhack; Omar Abdel-Wahab; Ari Melnick; Scott A Armstrong; Ross L Levine
Journal:  Nat Med       Date:  2015-10-05       Impact factor: 53.440
  5 in total
  23 in total

1.  Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status".

Authors:  Lindsay M LaFave; Wendy Béguelin; Richard Koche; Matt Teater; Barbara Spitzer; Alan Chramiec; Efthymia Papalexi; Matthew D Keller; Todd Hricik; Katerina Konstantinoff; Jean-Baptiste Micol; Benjamin Durham; Sarah K Knutson; John E Campbell; Gil Blum; Xinxu Shi; Emma H Doud; Andrei V Krivtsov; Young Rock Chung; Inna Khodos; Elisa de Stanchina; Ouathek Ouerfelli; Prasad S Adusumilli; Paul M Thomas; Neil L Kelleher; Minkui Luo; Heike Keilhack; Omar Abdel-Wahab; Ari Melnick; Scott A Armstrong; Ross L Levine
Journal:  Nat Med       Date:  2016-06-07       Impact factor: 53.440

Review 2.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

3.  Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells.

Authors:  Paolo Mellini; Biagina Marrocco; Diana Borovika; Lucia Polletta; Ilaria Carnevale; Serena Saladini; Giulia Stazi; Clemens Zwergel; Peteris Trapencieris; Elisabetta Ferretti; Marco Tafani; Sergio Valente; Antonello Mai
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

4.  Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.

Authors:  Lu Wang; Zibo Zhao; Patrick A Ozark; Damiano Fantini; Stacy A Marshall; Emily J Rendleman; Kira A Cozzolino; Nundia Louis; Xingyao He; Marc A Morgan; Yoh-Hei Takahashi; Clayton K Collings; Edwin R Smith; Panagiotis Ntziachristos; Jeffrey N Savas; Lihua Zou; Rintaro Hashizume; Joshua J Meeks; Ali Shilatifard
Journal:  Nat Med       Date:  2018-05-21       Impact factor: 53.440

5.  Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1.

Authors:  Yilei Zhang; Pranavi Koppula; Boyi Gan
Journal:  Cell Cycle       Date:  2019-03-30       Impact factor: 4.534

Review 6.  Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?

Authors:  Ewa M Michalak; Jane E Visvader
Journal:  Mol Oncol       Date:  2016-09-23       Impact factor: 6.603

Review 7.  New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma.

Authors:  Alexander Z Wei; Ashray B Maniar; Richard D Carvajal
Journal:  Cancer Gene Ther       Date:  2022-03-02       Impact factor: 5.854

8.  Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.

Authors:  Asmaa Mosbeh; Khalil Halfawy; Wael S Abdel-Mageed; Dina Sweed; Mohamed H Abdel Rahman
Journal:  Cancer Genet       Date:  2018-04-09

Review 9.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314

Review 10.  Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.

Authors:  Michele Carbone; J William Harbour; James Brugarolas; Angela Bononi; Ian Pagano; Anwesha Dey; Thomas Krausz; Harvey I Pass; Haining Yang; Giovanni Gaudino
Journal:  Cancer Discov       Date:  2020-07-20       Impact factor: 38.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.